Hepatocellular Carcinoma
Conditions
Keywords
hypovolemic phlebotomy, low central venous pressure, goal-directed, laparoscopic hepatectomy
Brief summary
The goal of this clinical trial is to learn about goal-directed LCVP based on hypovolemic phlebotomy (HP) in laparoscopic hepatectomy. The main questions it aims to answer are: 1. The safety and feasibility of HP 2. To evaluate whether HP can reduce perioperative blood transfusion ratio Participants undergoing liver resection with HP was performed by the anesthesiologist. Blood was withdrawn approximately 30 min prior to the initiation of liver parenchymal transection from central venous. The aim was to maintain the CVP between 0 to 5 cmH2O. HP volume was 5-10 mL/kg of patient body weight, generally. Participants in control group undergoing liver resection without HP.
Interventions
PROCEDUREhypovolemic phlebotomy
hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Hepatocellular Carcinoma * Preference for laparoscopic hepatectomy and patient agreement
Exclusion criteria
* Age \<18 years * Pregnancy * Refusal of blood product transfusion * Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) * History of significant cerebrovascular disease * Restrictive or obstructive pulmonary disease * Uncontrolled hypertension * Renal dysfunction (glomerular filtration rate \<60 mL/min), * Hemoglobin \<100 g/L * Abnormal coagulation values (international normalized ratio \>1.5 not on warfarin and/or platelet count \<100 ×109/L) * Evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L) * Presence of active infection * Preoperative autologous blood donation * Patients were not allowed to receive erythropoietin at any time during the index hospitalization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of allogeneic red blood cell products transfusion | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | The primary end point of the study was the proportion of patients who required transfusion of allogeneic red blood cell products during laparoscopic hepatectomy or at any time during the hospitalization during the index admission. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The volume of Intraoperative blood loss | From the start of operation until the end of operation (during the operation). | — |
| The volume of Allogeneic transfusion (perioperative) | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | — |
| The volume of Allogeneic transfusion (postoperative) | From the end of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | — |
| The volume of Allogeneic transfusion (intraoperative) | From the start of operation until the end of operation. | — |
| The volume of Fresh frozen plasm (FFP) transfusion | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | — |
| The volume of Platelets transfusion | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | — |
| The volume of Albumin transfusion | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 12 months. | — |
| Perioperative lowest concentration of Hb | From the start of operation until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months. | — |
| The volume of Phlebotomy | From the start of operation until the end of operation. | — |
| Lowest central venous pressure (CVP) | From the start of operation until the end of operation (during the operation). | — |
| time of pringle maneuver | From the start of operation until the end of operation. | — |
| number of pringle maneuver | From the start of operation until the end of operation. | how many patients have the pringle maneuver |
| operating time | From the start of operation until the end of operation. | — |
| The proportion of laparoscopic hepatectomy converted to open liver resection | From the start of operation until the end of operation. | — |
| Length of stay | From date of hospitalization until the date of discharge from hospital or date of death from any cause, whichever came first. assessed up to 12 months | — |
| Number of Participants with postoperative complications (overall) | From date of operation until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 months. | — |
| Pre-transection central venous pressure (CVP), (basic CVP) | From the start of anesthesia induction until the star of operation. | — |
Countries
China
Contacts
Primary ContactShijiang Liu, MD
Backup ContactYue Wang
Outcome results
None listed